RxDoctor Payments DataLook up a doctor →

Imran Aslam, MD

Dermatology · Bismarck, NDNPI 1992199244

Payments from drug & device makers

$280,487in general payments, 2019–2025

Across 1,017 payments — averaging $275.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$92K
  • LEO Pharma Inc.$77K
  • Johnson & Johnson$39K
  • Incyte Corporation$35K
  • E.r. Squibb & Sons, L.L.C.$11K
  • Sanofi$8K
  • plus $19K from 25 others

What the payments were for

  • Consulting fees$30,61111%
  • Speaking & faculty fees$217,43178%
  • Travel & lodging$9,0383%
  • Food & beverage$23,1048%
  • Education$3020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$280,487 in reported general payments places this provider in the 95th percentile of 29 dermatology providers in North Dakota.

See all dermatology providers in North Dakota

Medicare billing

Part B allowed, 2024
$174,431
Medicare patients
421
Services billed
2,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZoryveRoflumilast14$12,086
Tacrolimus23$2,863
Clobetasol Propionate51$2,694
Fluorouracil14$811
Triamcinolone Acetonide71$717
Ketoconazole19$248
Clotrimazole16$243
Doxycycline Hyclate12$168
Hydroxychloroquine Sulfate11$150
Hydrocortisone21$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$1,594$12,08614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 dermatology providers in North Dakota.

Other dermatology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →